Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's PR-006?
PR-006 is a gene therapy commercialized by Eli Lilly and Co, with a leading Phase II program in Frontotemporal Dementia...